发布求助
文献互助 智能选刊 最新文献

Leukemia & Lymphoma最新文献

筛选
英文 中文
Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis. teclistamab治疗复发/难治性多发性骨髓瘤的安全性和有效性：来自多中心、回顾性研究和描述性荟萃分析的结果
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-01-05 DOI: 10.1080/10428194.2024.2446617
Gaurav Varma, Lindsay Fogel, Beth Gordon, Mateo Mejia Saldarriaga, Jaeil Ahn, Adolfo Aleman, Jessica Caro, Maya C Rosenberg, Jorge Monge, Harsh Parmar, David Kaminetzky, Tibor Moskovits, David S Siegel, Gareth J Morgan, Ruben Niesvizky, Faith E Davies, Noa Biran
{"title":"Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis.","authors":"Gaurav Varma, Lindsay Fogel, Beth Gordon, Mateo Mejia Saldarriaga, Jaeil Ahn, Adolfo Aleman, Jessica Caro, Maya C Rosenberg, Jorge Monge, Harsh Parmar, David Kaminetzky, Tibor Moskovits, David S Siegel, Gareth J Morgan, Ruben Niesvizky, Faith E Davies, Noa Biran","doi":"10.1080/10428194.2024.2446617","DOIUrl":"https://doi.org/10.1080/10428194.2024.2446617","url":null,"abstract":"<p><p>Patients participating in clinical trials are highly selected and may not represent the general population. The pivotal study of teclistamab (MajesTEC-1), a B-cell maturation antigen (BCMA)xCD3 bispecific antibody, demonstrated impressive response rates and progression free survival in relapsed/refractory multiple myeloma (RRMM) with acceptable toxicity. We performed a retrospective study of 58 patients treated as standard of care at four US academic centers to determine how these results translated to the real-world. Most patients (87.9%) would not have been eligible for the MajesTEC-1 study due to either disease related factors, patient related comorbidities or socio-economic/geographical factors. Despite these 'less-favorable' characteristics we observed similar efficacy and toxicity to MajesTEC-1. A meta-analysis with six other published real-world series (n = 546) confirmed these results. These data support the significant clinical activity of teclistamab in RRMM and highlights the importance of real-world data to accompany the pivotal trial data to further inform daily clinical practice.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2025-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in the treatment of high burden Follicular lymphoma: a Comprehensive review. 高负荷滤泡性淋巴瘤治疗进展综述。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-01-05 DOI: 10.1080/10428194.2024.2447371
Efrat Luttwak, Anita Kumar, Gilles Salles
{"title":"Advances in the treatment of high burden Follicular lymphoma: a Comprehensive review.","authors":"Efrat Luttwak, Anita Kumar, Gilles Salles","doi":"10.1080/10428194.2024.2447371","DOIUrl":"https://doi.org/10.1080/10428194.2024.2447371","url":null,"abstract":"<p><p>Follicular lymphoma (FL) represents the second most frequent type of non-Hodgkin lymphoma and the most common indolent histology. The disease course of FL is heterogeneous, likely resulting from diverse molecular and immunological features that drive a broad spectrum of clinical presentations. While some patients with low-volume and asymptomatic disease are suitable for observation, patients with high tumor burden, advanced-stage, or symptomatic disease more often necessitate treatment initiation. The decision to begin therapy is personalized and typically initiated when GELF criteria are met. The introduction of novel agents has modified the treatment landscape for FL, allowing for more personalized strategies based on the specific characteristics of patients and diseases. In this review, we discuss the indications for treatment initiation and optimization, focusing on long-term follow-up of pivotal studies and emerging non-chemotherapy regimens. We further consider effective novel combination regimens and future directions for the evolution of frontline immunotherapy for the treatment of patients with FL.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-12"},"PeriodicalIF":2.2,"publicationDate":"2025-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PBVD regimen (pegylated liposomal doxorubicin, bleomycin, vincristine, dacarbazine) in classical Hodgkin lymphoma patients with cardiovascular risk factors: a retrospective study. 具有心血管危险因素的经典霍奇金淋巴瘤患者的PBVD治疗方案（聚乙二醇化脂质体阿霉素、博来霉素、长春新碱、达卡巴嗪）：一项回顾性研究
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-01-05 DOI: 10.1080/10428194.2024.2447888
Jia Jin, Dan-Dan Meng, Yu Wen, Qun-Ling Zhang, Fang-Fang Lv, Guang-Liang Chen, Xue-Jun Ma, Bao-Hua Yu, Sheng-Jian Zhang, Chang Liu, Zu-Guang Xia
{"title":"PBVD regimen (pegylated liposomal doxorubicin, bleomycin, vincristine, dacarbazine) in classical Hodgkin lymphoma patients with cardiovascular risk factors: a retrospective study.","authors":"Jia Jin, Dan-Dan Meng, Yu Wen, Qun-Ling Zhang, Fang-Fang Lv, Guang-Liang Chen, Xue-Jun Ma, Bao-Hua Yu, Sheng-Jian Zhang, Chang Liu, Zu-Guang Xia","doi":"10.1080/10428194.2024.2447888","DOIUrl":"https://doi.org/10.1080/10428194.2024.2447888","url":null,"abstract":"<p><p>This retrospective study aimed to evaluate the efficacy and safety of PBVD (pegylated liposomal doxorubicin [PLD], bleomycin, vinblastine, and dacarbazine) in the first-line treatment of classical Hodgkin lymphoma (cHL) patients with cardiovascular risk factors. Overall, 84 patients (53 had stage I-II and 31 had stage III-IV disease) received PBVD. The median PLD treatment duration was 16 weeks (interquartile range [IQR]: 8-24) for stage I-II and 24 weeks (IQR: 12-24) for stage III-IV. Among them, 56 (66.7%) received radiotherapy (45 with stage I-II and 11 with stage III-IV disease). Seventy-four (88.1%) patients achieved complete response. At a median follow-up of 49.7 months, 2- and 5-year progression-free survival were both 83.2%, and overall survival was 98.7% and 94.9%. Adverse events occurred in 73.8% of patients, including 7.1% cardiac events. No treatment-related deaths were observed. This approach showed a favorable benefit-to-risk profile in this population.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2025-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Salvage therapy for Burkitt lymphoma with glofitamab: a case report. 格非他单抗治疗伯基特淋巴瘤1例。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-01-03 DOI: 10.1080/10428194.2024.2447882
Pedro Martins Almeida, Thomas Relander, Ola Linden
{"title":"Salvage therapy for Burkitt lymphoma with glofitamab: a case report.","authors":"Pedro Martins Almeida, Thomas Relander, Ola Linden","doi":"10.1080/10428194.2024.2447882","DOIUrl":"https://doi.org/10.1080/10428194.2024.2447882","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-4"},"PeriodicalIF":2.2,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142922042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The multi-faceted roles of MYC in the prognosis of chronic lymphocytic leukemia. MYC 在慢性淋巴细胞白血病预后中的多重作用。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-01-02 DOI: 10.1080/10428194.2024.2447362
Loic Ysebaert, Pierre-Luc Mouchel, Camille Laurent, Anne Quillet-Mary
{"title":"The multi-faceted roles of MYC in the prognosis of chronic lymphocytic leukemia.","authors":"Loic Ysebaert, Pierre-Luc Mouchel, Camille Laurent, Anne Quillet-Mary","doi":"10.1080/10428194.2024.2447362","DOIUrl":"https://doi.org/10.1080/10428194.2024.2447362","url":null,"abstract":"<p><p>In this review, we focus on the pro-oncogene MYC, the modes of deregulation in mouse and human B-cells, its undisputable importance in the evaluation of biological prognostication of patients, but also how it impacts on response to modern therapeutics, and how it should be targeted to improve the overall survival of chronic lymphocytic lymphoma (CLL) patients. After an overview of the current understanding of the molecular dysregulation of c-MYC, we will show how CLL, both in its indolent and transformed phases, has developed among other B-cell lymphomas a tight regulation of its expression through the chronic activation of B-Cell Receptors (among others). This is particularly important if one desires to understand the mechanisms at stake in the over-expression of c-MYC especially in the lymph nodes compartment. So doing, we will show how this oncogene orchestrates pivotal cellular functions such as metabolism, drug resistance, proliferation and histologic transformation (Richter syndrome).</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-13"},"PeriodicalIF":2.2,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142915450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nodular lymphocyte-predominant Hodgkin lymphoma revisited: current management strategies and future perspectives. 重新审视结节淋巴细胞为主的霍奇金淋巴瘤：当前的管理策略和未来的展望。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-01-02 DOI: 10.1080/10428194.2024.2447886
Dennis A Eichenauer, Peter Borchmann
{"title":"Nodular lymphocyte-predominant Hodgkin lymphoma revisited: current management strategies and future perspectives.","authors":"Dennis A Eichenauer, Peter Borchmann","doi":"10.1080/10428194.2024.2447886","DOIUrl":"https://doi.org/10.1080/10428194.2024.2447886","url":null,"abstract":"<p><p>Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma entity accounting for ≈5% of all Hodgkin lymphoma (HL) cases. As some characteristics of NLPHL resemble B-cell non-Hodgkin lymphoma (B-NHL), nodular lymphocyte-predominant B-cell lymphoma has been proposed as alternative name. Unlike classical HL (cHL), NLPHL is mostly diagnosed in early stages. The clinical course is usually indolent. Overall, NLPHL patients have an excellent prognosis and the majority experiences long-term survival. Except for stage IA disease which is sufficiently treated with radiotherapy alone, treatment of newly diagnosed NLPHL is often very similar to cHL. However, activity has also been demonstrated for rituximab-containing protocols applied in B-NHL. Second-line treatment is chosen individually and mostly less intensive than in cHL. Chimeric antigen receptor T-cell therapy and bispecific antibodies may be part of future treatment strategies for NLPHL. This review aims at summarizing recent data on treatment approaches and discussing future perspectives in NLPHL.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-8"},"PeriodicalIF":2.2,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142915446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular, clinical, and prognostic implications of RAS pathway alterations in adult acute myeloid leukemia. 成人急性髓性白血病RAS通路改变的分子、临床和预后意义。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-01-02 DOI: 10.1080/10428194.2024.2441855
Fenghong Zhang, Yizi Liu, Yiyan Zhu, Qingyuan Wang, Xiangyu Zhao, Qian Wang, Yu Chen, Suning Chen
{"title":"Molecular, clinical, and prognostic implications of RAS pathway alterations in adult acute myeloid leukemia.","authors":"Fenghong Zhang, Yizi Liu, Yiyan Zhu, Qingyuan Wang, Xiangyu Zhao, Qian Wang, Yu Chen, Suning Chen","doi":"10.1080/10428194.2024.2441855","DOIUrl":"https://doi.org/10.1080/10428194.2024.2441855","url":null,"abstract":"<p><p>Alterations in the RAS pathway underscore the pathogenic complexity of acute myeloid leukemia (AML), yet the full spectrum, including <i>CBL</i>, <i>NF1</i>, <i>PTPN11</i>, <i>KRAS</i>, and <i>NRAS</i>, remains to be fully elucidated. In this retrospective study of 735 adult AML patients, the incidence of RAS pathway alterations was 32.4%, each with distinct clinical characteristics. Venetoclax combined with hypomethylating agents (VEN + HMA) did not significantly improve response rates compared to intensive chemotherapy (IC) group. In the IC group, <i>PTPN11</i> mutations in the N-SH2 domain showed a trend toward poorer prognosis, though not statistically significant in multivariate analysis, while <i>NRAS</i> mutations correlated with improved outcomes. In the VEN + HMA group, <i>PTPN11</i> mutations in the N-SH2 domain emerged as an independent adverse prognostic marker. <i>NRAS</i> or <i>KRAS</i> mutations showed no survival advantage compared to wild-type, aligning with their intermediate-risk classification in the 2024 ELN guidelines. These findings emphasize the need for treatment-specific risk stratification for RAS pathway mutations in AML.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-11"},"PeriodicalIF":2.2,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142915388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Persistent parvovirus B19 infection in a heavily pretreated lymphoma patient receiving mosunetuzumab. 一名接受莫苏尼珠单抗治疗的重度预处理淋巴瘤患者持续感染 parvovirus B19。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-01-01 Epub Date: 2024-09-23 DOI: 10.1080/10428194.2024.2404246
Wolfgang Füreder, Cathrin Skrabs, Selma Tobudic
{"title":"Persistent parvovirus B19 infection in a heavily pretreated lymphoma patient receiving mosunetuzumab.","authors":"Wolfgang Füreder, Cathrin Skrabs, Selma Tobudic","doi":"10.1080/10428194.2024.2404246","DOIUrl":"10.1080/10428194.2024.2404246","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"163-165"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142308064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enasidenib in relapsed aggressive systemic mastocytosis with IDH2 mutation. 依那西尼治疗IDH2突变的复发侵袭性系统性肥大细胞增多症
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-01-01 Epub Date: 2024-10-22 DOI: 10.1080/10428194.2024.2410942
Alejandro Del Rio Verduzco, Ali Al Darobi, Alex Heimbigner, Hayley Heers, Matthew Ulrickson
{"title":"Enasidenib in relapsed aggressive systemic mastocytosis with IDH2 mutation.","authors":"Alejandro Del Rio Verduzco, Ali Al Darobi, Alex Heimbigner, Hayley Heers, Matthew Ulrickson","doi":"10.1080/10428194.2024.2410942","DOIUrl":"10.1080/10428194.2024.2410942","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"170-173"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142503149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CD1a + histiocytoses in primary myelofibrosis patients: just a casual association? A case report and systematic review of the literature. 原发性骨髓纤维化患者的CD1a +组织细胞增多：只是偶然的关联？一份病例报告及文献系统回顾。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-01-01 Epub Date: 2025-01-02 DOI: 10.1080/10428194.2024.2404247
Arturo Bonometti, Alexandar Tzankov, Ilaria Alborelli, Philip Went, Stefan Dirnhofer
{"title":"CD1a + histiocytoses in primary myelofibrosis patients: just a casual association? A case report and systematic review of the literature.","authors":"Arturo Bonometti, Alexandar Tzankov, Ilaria Alborelli, Philip Went, Stefan Dirnhofer","doi":"10.1080/10428194.2024.2404247","DOIUrl":"https://doi.org/10.1080/10428194.2024.2404247","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":"66 1","pages":"139-146"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142922043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信